News | November 30, 2022
Zydus enters into BTA for purchase from Watson Pharma
The Business Undertaking of Watson is engaged in the business of developing, manufacturing, marketing and sale of API.
The Business Undertaking of Watson is engaged in the business of developing, manufacturing, marketing and sale of API.
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Plans to double its manufacturing footprint to bolster the growth
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)